PRECIPIO INC
PRPONASDAQTrading Snapshot
- Day Range
- $17.30 β $19.73
- 52-Week Range
- $17.30 β $33.63
- Volume (shares)
- 35,650
- Avg Volume (shares)
- β
- Shares Outstanding
- 1.8M
- Next Earnings
- 2027-04-05
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $7M
- P/E Ratio
- β
- P/S Ratio
- 1.1x
- EPS (TTM)
- $-0.68
- Dividend Yield
- β
- Dilution (1yr)
- +7.5%
PRECIPIO INC
PRPOAbout PRECIPIO INC
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth
Precipio's third-quarter 2026 results show solid product revenue growth, improved profitability and bold expansion plans despite lingering liquidity concerns.

Precipio, Inc. (PRPO) Q3 2026 Earnings Call Transcript
Precipio, Inc. (PRPO) Q3 2026 Earnings Call Transcript

Precipio Announces Q3-2026 Financial Results
NEW HAVEN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics companyΒ Precipio, Inc. (NASDAQ: PRPO) announces third-quarter financial results for the quarter ending September 30, 2026.

Precipio Announces Q3-2026 Shareholder Update Call
NEW HAVEN, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. Β (NASDAQ: PRPO) , will be hosting its Q3-2026 shareholder update call on November 10th, 2026, at 5:00 PM ET.

Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average β Hereβs Why
Precipio, Inc. (NASDAQ: PRPO - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $25.20 and traded as low as $20.

Precipio: Management Dreams Big, Institutions Have A Toe In
Precipio is an established laboratory services provider in cancer diagnostics and has launched a razor and razor blade model for facilities to test their own samples on site. 16.6% of the stock is held by officers and di